Van ECK Associates Corp Has $378.52 Million Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Van ECK Associates Corp increased its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 107.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,841,652 shares of the company’s stock after acquiring an additional 2,506,417 shares during the period. Van ECK Associates Corp’s holdings in GE HealthCare Technologies were worth $378,520,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. State Street Corp boosted its holdings in GE HealthCare Technologies by 7.8% in the third quarter. State Street Corp now owns 18,615,890 shares of the company’s stock worth $1,747,101,000 after purchasing an additional 1,347,114 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of GE HealthCare Technologies by 7.2% during the 3rd quarter. Geode Capital Management LLC now owns 10,977,757 shares of the company’s stock worth $1,026,898,000 after acquiring an additional 733,819 shares in the last quarter. D1 Capital Partners L.P. acquired a new position in shares of GE HealthCare Technologies during the 3rd quarter valued at about $268,159,000. Charles Schwab Investment Management Inc. grew its holdings in GE HealthCare Technologies by 12.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,710,938 shares of the company’s stock valued at $254,422,000 after purchasing an additional 290,019 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in GE HealthCare Technologies by 29.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,233,603 shares of the company’s stock worth $209,624,000 after acquiring an additional 512,778 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have commented on the company. Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their price target for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. Wells Fargo & Company lifted their price objective on GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, GE HealthCare Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.77.

GE HealthCare Technologies Stock Performance

Shares of GE HealthCare Technologies stock opened at $85.90 on Thursday. The company’s 50 day moving average price is $83.58 and its two-hundred day moving average price is $85.39. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. GE HealthCare Technologies Inc. has a fifty-two week low of $74.51 and a fifty-two week high of $94.55. The firm has a market capitalization of $39.25 billion, a P/E ratio of 23.60, a P/E/G ratio of 2.93 and a beta of 1.15.

GE HealthCare Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be given a dividend of $0.035 per share. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. The ex-dividend date of this dividend is Tuesday, January 14th. This represents a $0.14 annualized dividend and a dividend yield of 0.16%. GE HealthCare Technologies’s dividend payout ratio is presently 3.85%.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.